Anticoagulant Recalled Due to Incorrect Tablet Strength in Bottle

At this time, there have been no reports of harm related to this recall
At this time, there have been no reports of harm related to this recall

Bristol-Myers Squibb is recalling one lot of Eliquis (apixaban) 5mg tablets after it was discovered that one of the bottles contained the 2.5mg tablets instead of the labeled 5mg tablets.

The recall is specific to Eliquis 5mg Tablets (60-count bottle) Lot# HN0063 with expiration date of September 2019. The two tablet strengths have distinct differences in appearance, which may reduce the risk of administering the wrong dose. However, if a patient fails to notice these differences, they may be at increased risk of developing stroke, deep vein thrombosis (DVT)/pulmonary embolism (PE), and/or systemic thromboembolism due to a subtherapeutic dose of apixaban.

At this time, there have been no reports of harm related to this recall. The recall is being conducted to the retail/dispensing level.  

Related Articles

Eliquis is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; for the prophylaxis of DVT, which may lead to PE, in patients who have undergone hip or knee replacement surgery; and for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.

For more information call (800) 332-2056 or visit BMS.com.